BioSpace News Archive

Bio NC

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 06, 2023

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees stock options to purchase an aggregate of 80,700 shares, and restricted stock units covering an aggregate of 38,600 shares, of BioCryst common stock.

November 6, 2023
·
1 min read
Drug Development

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a corporate update.

November 6, 2023
·
7 min read
Business

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

November 6, 2023
·
14 min read
Business

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.

November 6, 2023
·
11 min read
Business

ICU Medical Announces Third Quarter 2023 Results

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended September 30, 2023.

November 6, 2023
·
19 min read
Business

Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its third quarter 2023 financial results after market close on Monday, November 13, 2023.

November 6, 2023
·
1 min read
Biotech Beach

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company’s management team will participate in the following investor conferences in November 2023.

November 6, 2023
·
1 min read
Biotech Beach

BioAtla to Participate in the Jefferies London Healthcare Conference 2023

BioAtla, Inc. announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 14–16, 2023.

November 6, 2023
·
2 min read
Business

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2023, and provided an update on corporate progress.

November 6, 2023
·
17 min read
Inotrem Receives Milestone Funding From the Crohn’s & Colitis Foundation IBD Ventures Program to Advance Its Inflammatory Bowel Disease Pipeline

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program.

November 6, 2023
·
3 min read